These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 16298120)

  • 1. [Antimitochondrial agents: a new class of anticancer agents].
    André N; Rome A; Carré M;
    Arch Pediatr; 2006 Jan; 13(1):69-75. PubMed ID: 16298120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of AIF-mediated caspase-independent programmed cell death.
    Lorenzo HK; Susin SA
    Drug Resist Updat; 2007 Dec; 10(6):235-55. PubMed ID: 18180198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in understanding the cell death pathways activated by anticancer therapy.
    Kim R
    Cancer; 2005 Apr; 103(8):1551-60. PubMed ID: 15742333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms.
    Reed JC
    Nat Clin Pract Oncol; 2006 Jul; 3(7):388-98. PubMed ID: 16826219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autophagy in cancer and chemotherapy.
    Yousefi S; Simon HU
    Results Probl Cell Differ; 2009; 49():183-90. PubMed ID: 19142622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of nitric oxide in cancer.
    Bonavida B; Khineche S; Huerta-Yepez S; Garbán H
    Drug Resist Updat; 2006 Jun; 9(3):157-73. PubMed ID: 16822706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment.
    Kim R; Emi M; Tanabe K; Uchida Y; Arihiro K
    Eur J Surg Oncol; 2006 Apr; 32(3):269-77. PubMed ID: 16431074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
    Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
    Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mitochondrial permeability in cancer drug development.
    Berridge MV; Herst PM; Lawen A
    Mol Nutr Food Res; 2009 Jan; 53(1):76-86. PubMed ID: 19035550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy.
    Tonissen KF; Di Trapani G
    Mol Nutr Food Res; 2009 Jan; 53(1):87-103. PubMed ID: 18979503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism.
    Pathania D; Millard M; Neamati N
    Adv Drug Deliv Rev; 2009 Nov; 61(14):1250-75. PubMed ID: 19716393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway.
    Yang X; Fraser M; Moll UM; Basak A; Tsang BK
    Cancer Res; 2006 Mar; 66(6):3126-36. PubMed ID: 16540663
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
    Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
    Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome inhibitors potentiate etoposide-induced cell death in human astrocytoma cells bearing a mutated p53 isoform.
    Ceruti S; Mazzola A; Abbracchio MP
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1424-34. PubMed ID: 16971507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondria as targets for cancer therapy.
    Ralph SJ; Neuzil J
    Mol Nutr Food Res; 2009 Jan; 53(1):9-28. PubMed ID: 19123183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitochondria as therapeutic targets for cancer chemotherapy.
    Galluzzi L; Larochette N; Zamzami N; Kroemer G
    Oncogene; 2006 Aug; 25(34):4812-30. PubMed ID: 16892093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autophagy signaling in cancer and its potential as novel target to improve anticancer therapy.
    Moretti L; Yang ES; Kim KW; Lu B
    Drug Resist Updat; 2007; 10(4-5):135-43. PubMed ID: 17627865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.
    Mita AC; Mita MM; Nawrocki ST; Giles FJ
    Clin Cancer Res; 2008 Aug; 14(16):5000-5. PubMed ID: 18698017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondria as cancer drug targets.
    Don AS; Hogg PJ
    Trends Mol Med; 2004 Aug; 10(8):372-8. PubMed ID: 15310457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.